Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Eyenovia Inc is a biotechnology business based in the US. Eyenovia shares (EYEN) are listed on the NASDAQ and all prices are listed in US Dollars. Eyenovia employs 43 staff and has a trailing 12-month revenue of around $10 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $1.98 |
|---|---|
| 52-week range | $1.52 - $6.63 |
| 50-day moving average | $1.84 |
| 200-day moving average | $2.54 |
| Wall St. target price | $13.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.54 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.98 from 2022-09-29
| 1 week (2022-09-23) | 3.66% |
|---|---|
| 1 month (2022-09-01) | -2.94% |
| 3 months (2022-07-01) | 4.21% |
| 6 months (2022-03-28) | -34.00% |
| 1 year (2021-10-01) | -59.59% |
|---|---|
| 2 years (2020-10-01) | -36.33% |
| 3 years (2019-10-01) | 3.46 |
| 5 years (2017-09-27) | N/A |
| Revenue TTM | $10 million |
|---|---|
| Gross profit TTM | $12.4 million |
| Return on assets TTM | -32.23% |
| Return on equity TTM | -105.3% |
| Profit margin | -171.64% |
| Book value | $0.70 |
| Market capitalisation | $65.3 million |
TTM: trailing 12 months
We're not expecting Eyenovia to pay a dividend over the next 12 months.
Over the last 12 months, Eyenovia's shares have ranged in value from as little as $1.52 up to $6.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyenovia's is 1.8643. This would suggest that Eyenovia's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Eyenovia, Inc. , a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.